Heart Disease and Heart Attacks are the number one killer of North Americans, and most people, worldwide. Nearly 1 in 3 deaths in the USA alone are attributed to Heart Attack and Stroke!
For 50% of these people, their "first" indication of a problem is a massive heart attack. They have no warning whatsoever.
Though taking blood pressure and heart rates couples with ultrasound techniques will sometimes indicate a problem, the fact remains that, only in 50% of all cases do these indicators work. Now, wouldn't it be great if there was a "Non-invasive" way of determining, with a lot more accuracy, if heart disease is prevalent in a patient, "before" the onset of a heart attack? Hey, wouldn't it be great if that test was no more bother than simply taking your blood pressure is?
Well, at this writing, there is such a device, currently in Clinical Trials trials, after 15 years of research and development in California Universities. Lexington BioSciences "HeartSentry" can measure something that has never been measured properly before. Endothelium
Endothelium, are the cells that line all arteries and are critical to the prevention of atherosclerosis, heart disease and stroke, the two leading causes of deaths worldwide (17.5 million people every year).
The significant value of measuring endothelial function is supported by many peer-reviewed studies.
For ease of use this new, life saving technology has been incorporated into a simple blood pressure cuff. Utilizing both blue tooth and cloud technology, the device to provide up-to-date, accurate readings of a patients complete cardiovascular health via electronic monitoring.
As you might expect, this is a significant development in a multi-billion dollar market, and all the patents and the technology are owned by a MicroCap Business, owned and operated by PHD's - LexingtonBioSciences
Disclosure: We own LNB Stock!
Question: Do you?